US Pharm. 2024;49(11):58.

Mucinex Launches Children’s OTC Soft Chews

When sickness strikes a house filled with little ones, the days ahead are tense and full of unknowns. Parents face the challenge of providing quick relief for their child’s symptoms and children who refuse to take liquid medicine. Mucinex Children’s Mighty Chews are made for children aged 6 years and older and are available in a mixed-berry flavor for both daytime and nighttime, each providing 4 hours of relief per dose. Mucinex Mighty Chews can be purchased at most retailers.

Drug With New Mechanism of Action to Treat Schizophrenia Now Available

The FDA has approved Cobenfy (xanomeline and trospium chloride) capsules for oral use for the treatment of schizophrenia in adults. It is the first antipsychotic drug approved to treat schizophrenia that targets cholinergic receptors as opposed to dopamine receptors, which have long been the standard of care.

Cobenfy should not be prescribed to patients with urinary retention, moderate or severe kidney or liver disease, gastric retention, untreated narrow-angle glaucoma, or a history of hypersensitivity to either Cobenfy or its components. The most common side effects are nausea, indigestion, constipation, vomiting, hypertension, abdominal pain, diarrhea, tachycardia (increased heartbeat), dizziness, and gastroesophageal reflux disease.

FDA Approves New Drug to Treat Niemann-Pick Disease Type C

The FDA has approved Aqneursa (levacetylleucine) for the treatment of neurologic symptoms associated with Niemann-Pick disease type C (NPC) in adults and pediatric patients weighing at least 15 kg. NPC is a rare genetic disease that results in progressive neurologic symptoms and organ dysfunction. It is caused by changes in either the NPC1 or NPC2 gene, affecting the necessary transport of cholesterol and other lipids within a cell. As a result, these cells do not function as they should, ultimately causing organ damage.

Self-Administered Flu Vaccine Approved for Younger Americans

The FDA has granted approval to MedImmune, LLC, for FluMist (Influenza Vaccine Live, Intranasal) for self- or caregiver administration for the prevention of influenza disease caused by influenza virus subtypes A and B in individuals aged 2 through 49 years. FluMist, which is sprayed into the nose, was initially approved by the FDA in 2003 for use in individuals aged 5 through 49 years, and in 2007 the FDA approved the use of FluMist to include children aged 2 through 5 years. It is the first vaccine to prevent influenza in the United States that does not need to be administered by a healthcare provider, the FDA noted.

Camber Pharmaceuticals Launches Generic Lunesta

On October 2, 2024, Camber Pharmaceuticals announced the addition of eszopiclone tablets, USP, to its product line. Between 50 and 70 million Americans suffer from chronic sleep disorders. Sleep deprivation can result in physical and mental health issues, increased risk of injury, reduced productivity, and even a higher chance of mortality.

Eszopiclone is indicated for the treatment of insomnia and been shown to decrease sleep latency and improve sleep maintenance. Eszopiclone tablets are available in 1-mg, 2-mg, and 3-mg strengths in 30- and 100-count bottles.

The content contained in this article is for informational purposes only. The content is not intended to be a substitute for professional advice. Reliance on any information provided in this article is solely at your own risk.

To comment on this article, contact rdavidson@uspharmacist.com.